Publications by authors named "Angelo Belotti"

Claim this Profile
L
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients.
Gregorio Barilà, Angela Grassi, Concetta Conticello, Roberto Mina, Chiara Marcon, Angelo Belotti

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.
Mario Boccadoro, Angelo Belotti, Felice Bombaci, Sara Bringhen, Gabriele Buda

BMC Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early identification of functional high-risk multiple myeloma patients after transplant: the predictive power of fat fraction and Response Assessment Category score in diffusion-weighted whole-body magnetic resonance imaging.
Angelo Belotti, Barbara Frittoli, Sofia Terlizzi, Rossella Ribolla, Claudia Crippa

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy.
Lorenzo Cani, Maria Teresa Petrucci, Katia Mancuso, Renato Zambello, Laura Paris, Angelo Belotti

Clin Lymphoma Myeloma Leuk· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.
Sara Bringhen, Lorenzo Cani, Elisabetta Antonioli, Daniele Derudas, Francesca Fazio, Angelo Belotti

Lancet Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, Massimo Offidani, Renato Zambello, Angelo Belotti

Eur J Haematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.
Sara Bringhen, Lorenzo Cani, Nicola Giuliani, Silvia Mangiacavalli, Giulia Benevolo, Angelo Belotti

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma.
Andrea Emanuele Guerini, Eneida Mataj, Paolo Borghetti, Luca Triggiani, Ludovica Pegurri, Angelo Belotti

Adv Radiat Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Foot Proprioception Through 3-Minute Walking Bouts with Ultra-Minimalist Shoes on Surfaces That Mimic Highly Rugged Natural Terrains.
Andrea Biscarini, Andrea Calandra, Alberto Marcucci, Roberto Panichi, Angelo Belotti

Biomimetics (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, Hang Quach, P Joy Ho, Angelo Belotti

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti

Leuk Lymphoma· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti, Luca Bertamini, Maddalena Arigoni

Blood Cancer J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy.
Francesca Fazio, Maria Teresa Petrucci, Laura Corvatta, Alfonso Piciocchi, Roberta Della Pepa, Angelo Belotti

EJHaem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Anna Furlan, Michele Cea, Laura Pavan, Monica Galli, Cristina Clissa, Angelo Belotti

Cancer Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Mattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, Angelo Belotti, Sonia Morè

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, Hang Quach, P Joy Ho, Angelo Belotti

N Engl J Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma.
Angelo Belotti, Rossella Ribolla, Claudia Crippa, Marco Chiarini, Viviana Giustini

Am J Hematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation.
Lorenzo Masina, Nicola Bianchetti, Angela Passi, Chiara Bottelli, Samuele Bagnasco, Angelo Belotti

Hematol Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
Stefania Oliva, Elisa Genuardi, Laura Paris, Mattia D'Agostino, Jennifer Rogers, Angelo Belotti

EClinicalMedicine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
Elena Zamagni, Stefania Oliva, Francesca Gay, Andrea Capra, Delia Rota-Scalabrini, Angelo Belotti

EClinicalMedicine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Silvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, Sara Pezzatti, Angelo Belotti

Haematologica· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Roberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, Laura Paris, Barbara Gamberi, Angelo Belotti

Lancet Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Antonella Bruzzese, Daniele Derudas, Monica Galli, Enrica Antonia Martino, Stefano Rocco, Angelo Belotti

Hematol Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
Luca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, Laura Paris, Sonia Morè, Angelo Belotti

J Clin Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment.
Andrea Emanuele Guerini, Alessandra Tucci, Filippo Alongi, Eneida Mataj, Angelo Belotti

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis